This makes completely no sense when they are growing revenue/profits over 50% easily and have zero debt and zero chance of going broke and they have an absolute market monopoly for years to come in the EPP space!
CUV has one orphan drug with a very limited market. They have no other products. The market look ahead and sees the Scenesse monopoly ending in a few years. The patents will begin to expire soon. It is possible sales will fall to almost zero if better or cheaper alternatives are available. That is how the pharmaceutical industry works.
This makes completely no sense when they are growing...
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.44 |
Change
-0.180(1.15%) |
Mkt cap ! $773.2M | |||
| Open | High | Low | Value | Volume |
| $15.60 | $15.75 | $15.39 | $751.4K | 48.47K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 173 | $15.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.54 | 209 | 1 |
View Market Depth
| Last trade - 16.10pm 16/07/2024 (20 minute delay) ? |
| CUV (ASX) Chart |